Literature DB >> 10978268

Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype.

S Bertolini1, A Cantafora, M Averna, C Cortese, C Motti, S Martini, G Pes, A Postiglione, C Stefanutti, I Blotta, L Pisciotta, M Rolleri, S Langheim, M Ghisellini, I Rabbone, S Calandra.   

Abstract

Seventy-one mutations of the low density lipoprotein (LDL) receptor gene were identified in 282 unrelated Italian familial hypercholesterolemia (FH) heterozygotes. By extending genotype analysis to families of the index cases, we identified 12 mutation clusters and localized them in specific areas of Italy. To evaluate the impact of these mutations on the clinical expression of FH, the clusters were separated into 2 groups: receptor-defective and receptor-negative, according to the LDL receptor defect caused by each mutation. These 2 groups were comparable in terms of the patients' age, sex distribution, body mass index, arterial hypertension, and smoking status. In receptor-negative subjects, LDL cholesterol was higher (+18%) and high density lipoprotein cholesterol lower (-5%) than the values found in receptor-defective subjects. The prevalence of tendon xanthomas and coronary artery disease (CAD) was 2-fold higher in receptor-negative subjects. In patients >30 years of age in both groups, the presence of CAD was related to age, arterial hypertension, previous smoking, and LDL cholesterol level. Independent contributors to CAD in the receptor-defective subjects were male sex, arterial hypertension, and LDL cholesterol level; in the receptor-negative subjects, the first 2 variables were strong predictors of CAD, whereas the LDL cholesterol level had a lower impact than in receptor-defective subjects. Overall, in receptor-negative subjects, the risk of CAD was 2.6-fold that of receptor-defective subjects. Wide interindividual variability in LDL cholesterol levels was found in each cluster. Apolipoprotein E genotype analysis showed a lowering effect of the epsilon2 allele and a raising effect of the epsilon4 allele on the LDL cholesterol level in both groups; however, the apolipoprotein E genotype accounted for only 4% of the variation in LDL cholesterol. Haplotype analysis showed that all families of the major clusters shared the same intragenic haplotype cosegregating with the mutation, thus suggesting the presence of common ancestors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10978268     DOI: 10.1161/01.atv.20.9.e41

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  17 in total

1.  Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction.

Authors:  Ingrid Brænne; Mariana Kleinecke; Benedikt Reiz; Elisabeth Graf; Tim Strom; Thomas Wieland; Marcus Fischer; Thorsten Kessler; Christian Hengstenberg; Thomas Meitinger; Jeanette Erdmann; Heribert Schunkert
Journal:  Eur J Hum Genet       Date:  2015-06-03       Impact factor: 4.246

2.  Recent origin and spread of a common Lithuanian mutation, G197del LDLR, causing familial hypercholesterolemia: positive selection is not always necessary to account for disease incidence among Ashkenazi Jews.

Authors:  R Durst; R Colombo; S Shpitzen; L B Avi; Y Friedlander; R Wexler; F J Raal; D A Marais; J C Defesche; M Y Mandelshtam; M J Kotze; E Leitersdorf; V Meiner
Journal:  Am J Hum Genet       Date:  2001-04-17       Impact factor: 11.025

3.  Structure-Function Relationships of LDL Receptor Missense Mutations Using Homology Modeling.

Authors:  Sureerut Porntadavity; Nutjaree Jeenduang
Journal:  Protein J       Date:  2019-08       Impact factor: 2.371

Review 4.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

Review 5.  Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review.

Authors:  L Iughetti; B Predieri; F Balli; S Calandra
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

Review 6.  Dominant versus recessive: molecular mechanisms in metabolic disease.

Authors:  Johannes Zschocke
Journal:  J Inherit Metab Dis       Date:  2008-10-21       Impact factor: 4.982

7.  In search of a genetic explanation for LDLc variability in an FH family: common SNPs and a rare mutation in MTTP explain only part of LDL variability in an FH family.

Authors:  Michael Winther; Shoshi Shpitzen; Or Yaacov; Jakob Landau; Limor Oren; Linda Foroozan-Rosenberg; Naama Lev Cohain; Daniel Schurr; Vardiela Meiner; Auryan Szalat; Shai Carmi; Michael R Hayden; Eran Leitersdorf; Ronen Durst
Journal:  J Lipid Res       Date:  2019-08-06       Impact factor: 5.922

8.  Upregulated expression of human cathelicidin LL-37 in hypercholesterolemia and its relationship with serum lipid levels.

Authors:  Yun-Xi Li; Bao-Zhen Li; Da-Zun Yan
Journal:  Mol Cell Biochem       Date:  2018-04-11       Impact factor: 3.396

9.  Molecular analysis of NPC1 and NPC2 gene in 34 Niemann-Pick C Italian patients: identification and structural modeling of novel mutations.

Authors:  Tatiana Fancello; Andrea Dardis; Camillo Rosano; Patrizia Tarugi; Barbara Tappino; Stefania Zampieri; Elisa Pinotti; Fabio Corsolini; Simona Fecarotta; Adele D'Amico; Maja Di Rocco; Graziella Uziel; Sebastiano Calandra; Bruno Bembi; Mirella Filocamo
Journal:  Neurogenetics       Date:  2009-02-28       Impact factor: 2.660

10.  Clinical course of homozygous familial hypercholesterolemia during childhood: report on 4 unrelated patients with homozygous or compound heterozygous mutations in the LDLR gene.

Authors:  Jolanta Kubalska; Magdalena Chmara; Janusz Limon; Aldona Wierzbicka; Sylwester Prokurat; Janina Szaplyko; Agnieszka Kowalik; Hanna Mierzewska; Joep C Defesche; Ewa Pronicka
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.